Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 1/2017

15.04.2016 | Original Article

Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry

verfasst von: P. Lennon, S. Deady, N. White, D. Lambert, M. L. Healy, A. Green, J. Kinsella, C. Timon, J. P. O’ Neill

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background and objectives

Medullary thyroid cancer consists of a spectrum of disease that ranges from extremely indolent tumors to aggressive types associated with a high mortality rate. The objective of our study is to evaluate the prognostic factors and outcomes of patients diagnosed with MTC in a homogenous population, and to examine patients diagnosed with MTC for mutations in the RET proto-oncogene from the same period.

Methods

A retrospective analysis of the National Cancer Registry in Ireland was undertaken, between 1998 and 2007. The Kaplan–Meier method was used to determine overall survival and factors predictive of outcome were determined by univariate and multivariate analysis by cox regression using Stata 13 software.

Main findings

Forty-three patients were diagnosed with medullary thyroid cancer, 55.8 % were female and 44.2 % were male. A median age of 52 was found. The overall median survival was 6.32 years and the 1- and 5-year overall survival was 88.37 and 62.79 %, respectively, with 10-year survival calculated at 48.63 %. On univariate analysis age, stage and surgical intervention were statistically significant indicators of prognosis. T stage and age remained statistically significant indicators of prognosis on multivariate analysis. Two patients with no history of MEN syndromes or family history of medullary thyroid cancer had RET proto-onocogene mutations.

Conclusions

Our patient cohort was substantially older and presented at an advanced T status than what is commonly seen in the literature. This may account for poor survival outcomes and the very low pick-up of RET mutations in sporadic medullary thyroid cancer.
Literatur
1.
Zurück zum Zitat Krampitz GW, Norton JA (2014) RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 120:1920–1931CrossRefPubMed Krampitz GW, Norton JA (2014) RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Cancer 120:1920–1931CrossRefPubMed
2.
Zurück zum Zitat Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 (see commetns). Cancer 83:2638–2648CrossRefPubMed Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 (see commetns). Cancer 83:2638–2648CrossRefPubMed
3.
Zurück zum Zitat Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH (2000) Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88:1139–1148CrossRefPubMed
4.
Zurück zum Zitat Chen H, Sippel RS, O’Dorisio MS et al (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783CrossRefPubMedPubMedCentral Chen H, Sippel RS, O’Dorisio MS et al (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775–783CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat O’Brien K, Comber H, Sharp L (2014) Completeness of case ascertainment at the Irish National Cancer Registry. Ir J Med Sci 183:219–224CrossRefPubMed O’Brien K, Comber H, Sharp L (2014) Completeness of case ascertainment at the Irish National Cancer Registry. Ir J Med Sci 183:219–224CrossRefPubMed
10.
Zurück zum Zitat Perros P, Boelaert K, Colley S et al (2014) Guidelines for the management of thyroid cancer. Clin Endocrinol 81(Suppl 1):1–122CrossRef Perros P, Boelaert K, Colley S et al (2014) Guidelines for the management of thyroid cancer. Clin Endocrinol 81(Suppl 1):1–122CrossRef
11.
Zurück zum Zitat Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084CrossRefPubMed Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077–6084CrossRefPubMed
12.
Zurück zum Zitat Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL (2005) Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445–1450CrossRefPubMed Clark JR, Fridman TR, Odell MJ, Brierley J, Walfish PG, Freeman JL (2005) Prognostic variables and calcitonin in medullary thyroid cancer. Laryngoscope 115:1445–1450CrossRefPubMed
13.
Zurück zum Zitat Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed Cupisti K, Wolf A, Raffel A et al (2007) Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution’s experience over 20 years. Ann Surg 246:815–821CrossRefPubMed
14.
Zurück zum Zitat de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736CrossRef de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736CrossRef
15.
Zurück zum Zitat Hyer SL, Vini L, A’Hern R, Harmer C (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 26:686–690 Hyer SL, Vini L, A’Hern R, Harmer C (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 26:686–690
16.
Zurück zum Zitat Pelizzo MR, Boschin IM, Bernante P et al (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 33:493–497 Pelizzo MR, Boschin IM, Bernante P et al (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 33:493–497
17.
Zurück zum Zitat Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 69:497–505CrossRef Rendl G, Manzl M, Hitzl W, Sungler P, Pirich C (2008) Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol 69:497–505CrossRef
18.
Zurück zum Zitat Rios A, Rodriguez JM, Acosta JM et al (2010) Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol 17:2444–2451CrossRefPubMed Rios A, Rodriguez JM, Acosta JM et al (2010) Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol 17:2444–2451CrossRefPubMed
19.
Zurück zum Zitat Saad MF, Ordonez NG, Rashid RK et al (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63:319–342CrossRefPubMed Saad MF, Ordonez NG, Rashid RK et al (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63:319–342CrossRefPubMed
20.
Zurück zum Zitat Bergholm U, Adami HO, Bergstrom R, Backdahl M, Akerstrom G (1990) Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand 156:37–46PubMed Bergholm U, Adami HO, Bergstrom R, Backdahl M, Akerstrom G (1990) Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand 156:37–46PubMed
21.
Zurück zum Zitat Kandil E, Gilson MM, Alabbas HH, Tufaro AP, Dackiw A, Tufano RP (2011) Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol 18:1028–1034CrossRefPubMed Kandil E, Gilson MM, Alabbas HH, Tufaro AP, Dackiw A, Tufano RP (2011) Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer. Ann Surg Oncol 18:1028–1034CrossRefPubMed
22.
Zurück zum Zitat Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol 48:265–273CrossRef Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol 48:265–273CrossRef
23.
Zurück zum Zitat Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134–2142CrossRefPubMed
24.
Zurück zum Zitat Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L (1996) Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77:1556–1565CrossRefPubMed
25.
Zurück zum Zitat Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687CrossRefPubMed
26.
Zurück zum Zitat Fife KM, Bower M, Harmer CL (1996) Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 22:588–591 Fife KM, Bower M, Harmer CL (1996) Medullary thyroid cancer: the role of radiotherapy in local control. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 22:588–591
27.
Zurück zum Zitat Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR (2014) The Effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 99:448–454CrossRefPubMed Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR (2014) The Effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 99:448–454CrossRefPubMed
28.
Zurück zum Zitat Balentine CJ, Chen H (2015) Chasing calcitonin: reoperations for medullary thyroid carcinoma. Ann Surg Oncol 22:7–8CrossRefPubMed Balentine CJ, Chen H (2015) Chasing calcitonin: reoperations for medullary thyroid carcinoma. Ann Surg Oncol 22:7–8CrossRefPubMed
29.
Zurück zum Zitat American Thyroid Association Guidelines Task F, Kloos RT, Eng C et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid Off J Am Thyroid Assoc 19:565–612CrossRef American Thyroid Association Guidelines Task F, Kloos RT, Eng C et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid Off J Am Thyroid Assoc 19:565–612CrossRef
30.
Zurück zum Zitat Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880–887 (discussion 887–888) CrossRefPubMedPubMedCentral Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229:880–887 (discussion 887–888) CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Oskam IM, Hoebers F, Balm AJ et al (2008) Neck management in medullary thyroid carcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 34:71–76 Oskam IM, Hoebers F, Balm AJ et al (2008) Neck management in medullary thyroid carcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 34:71–76
32.
Zurück zum Zitat Weber T, Schilling T, Frank-Raue K et al (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044–1049CrossRefPubMed Weber T, Schilling T, Frank-Raue K et al (2001) Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 130:1044–1049CrossRefPubMed
33.
Zurück zum Zitat Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95:2655–2663CrossRefPubMed
34.
Zurück zum Zitat Emmertsen K (1985) Medullary thyroid carcinoma and calcitonin. Dan Med Bull 32:1–28PubMed Emmertsen K (1985) Medullary thyroid carcinoma and calcitonin. Dan Med Bull 32:1–28PubMed
35.
Zurück zum Zitat Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H (2004) Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 28:1271–1274CrossRefPubMed Ukkat J, Gimm O, Brauckhoff M, Bilkenroth U, Dralle H (2004) Single center experience in primary surgery for medullary thyroid carcinoma. World J Surg 28:1271–1274CrossRefPubMed
36.
Zurück zum Zitat Rowland KJ, Jin LX, Moley JF (2015) Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol 22:96–102CrossRefPubMed Rowland KJ, Jin LX, Moley JF (2015) Biochemical cure after reoperations for medullary thyroid carcinoma: a meta-analysis. Ann Surg Oncol 22:96–102CrossRefPubMed
37.
Zurück zum Zitat Fersht N, Vini L, A’Hern R, Harmer C (2001) The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid Off J Am Thyroid Assoc 11:1161–1168CrossRef Fersht N, Vini L, A’Hern R, Harmer C (2001) The role of radiotherapy in the management of elevated calcitonin after surgery for medullary thyroid cancer. Thyroid Off J Am Thyroid Assoc 11:1161–1168CrossRef
38.
Zurück zum Zitat Schwartz DL, Rana V, Shaw S et al (2008) Postoperative radiotherapy for advanced medullary thyroid cancer–local disease control in the modern era. Head Neck 30:883–888CrossRefPubMed Schwartz DL, Rana V, Shaw S et al (2008) Postoperative radiotherapy for advanced medullary thyroid cancer–local disease control in the modern era. Head Neck 30:883–888CrossRefPubMed
39.
Zurück zum Zitat Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid Off J Am Thyroid Assoc 6:305–310CrossRef Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid Off J Am Thyroid Assoc 6:305–310CrossRef
40.
Zurück zum Zitat Santoro M, Rosati R, Grieco M et al (1990) The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5:1595–1598PubMed Santoro M, Rosati R, Grieco M et al (1990) The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5:1595–1598PubMed
41.
Zurück zum Zitat Herrmann ME, Talpos GB, Mohamed AN et al (1991) Genetic markers in thyroid tumors. Surgery 110:941–947 (discussion 947–948) PubMed Herrmann ME, Talpos GB, Mohamed AN et al (1991) Genetic markers in thyroid tumors. Surgery 110:941–947 (discussion 947–948) PubMed
42.
Zurück zum Zitat Eng C, Smith DP, Mulligan LM et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241CrossRefPubMed Eng C, Smith DP, Mulligan LM et al (1994) Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3:237–241CrossRefPubMed
43.
Zurück zum Zitat Perri F, Pezzullo L, Chiofalo MG et al (2014) Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol 94(1):55–63CrossRefPubMed Perri F, Pezzullo L, Chiofalo MG et al (2014) Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol 94(1):55–63CrossRefPubMed
44.
Zurück zum Zitat Santoro M, Carlomagno F, Romano A et al (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–383CrossRefPubMed Santoro M, Carlomagno F, Romano A et al (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381–383CrossRefPubMed
45.
Zurück zum Zitat Dvorakova S, Vaclavikova E, Sykorova V et al (2008) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284:21–27CrossRefPubMed Dvorakova S, Vaclavikova E, Sykorova V et al (2008) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284:21–27CrossRefPubMed
46.
Zurück zum Zitat Marsh DJ, Learoyd DL, Andrew SD et al (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44:249–257CrossRef Marsh DJ, Learoyd DL, Andrew SD et al (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol 44:249–257CrossRef
48.
Zurück zum Zitat Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 30:134–141CrossRef Wells SA Jr, Robinson BG, Gagel RF et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 30:134–141CrossRef
49.
Zurück zum Zitat Elisei R, Schlumberger MJ, Muller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 31:3639–3646CrossRef Elisei R, Schlumberger MJ, Muller SP et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol Off J Am Soc Clin Oncol 31:3639–3646CrossRef
50.
Zurück zum Zitat Simbolo M, Mian C, Barollo S et al (2014) High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Arch Int J Pathol 465:73–78CrossRef Simbolo M, Mian C, Barollo S et al (2014) High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas. Virchows Arch Int J Pathol 465:73–78CrossRef
51.
Zurück zum Zitat Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed
52.
Zurück zum Zitat Bairead E, Harmon DL, Curtis AM et al (2003) Association of NOD2 with Crohn’s disease in a homogenous Irish population. Eur J Hum Genet EJHG 11:237–244CrossRefPubMed Bairead E, Harmon DL, Curtis AM et al (2003) Association of NOD2 with Crohn’s disease in a homogenous Irish population. Eur J Hum Genet EJHG 11:237–244CrossRefPubMed
53.
Zurück zum Zitat Dunne C, Crowley J, Hagan R, Rooney G, Lawlor E (2008) HLA-A, B, Cw, DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous Irish population. Int J Immunogenet 35:295–302CrossRefPubMed Dunne C, Crowley J, Hagan R, Rooney G, Lawlor E (2008) HLA-A, B, Cw, DRB1, DQB1 and DPB1 alleles and haplotypes in the genetically homogenous Irish population. Int J Immunogenet 35:295–302CrossRefPubMed
54.
Zurück zum Zitat Tian C, Plenge RM, Ransom M et al (2008) Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet 4:e4CrossRefPubMedPubMedCentral Tian C, Plenge RM, Ransom M et al (2008) Analysis and application of European genetic substructure using 300 K SNP information. PLoS Genet 4:e4CrossRefPubMedPubMedCentral
Metadaten
Titel
Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry
verfasst von
P. Lennon
S. Deady
N. White
D. Lambert
M. L. Healy
A. Green
J. Kinsella
C. Timon
J. P. O’ Neill
Publikationsdatum
15.04.2016
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 1/2017
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-016-1455-1

Weitere Artikel der Ausgabe 1/2017

Irish Journal of Medical Science (1971 -) 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.